MOL #72124

Application of homology modeling to generate CYP1A1 mutants with enhanced

activation of the cancer chemotherapeutic prodrug dacarbazine

Benjamin C. Lewis, Peter I. Mackenzie, and John O. Miners.

Department of Clinical Pharmacology, School of Medicine, Flinders University, Adelaide, Australia.

MOL #72124

Running Title: Activation of dacarbazine by CYP1A1 mutants

Corresponding author:

Professor John Miners, Department of Clinical Pharmacology, Flinders University

School of Medicine, Flinders Medical Centre, Bedford Park, SA 5042, Australia

Telephone: 61 8 8204 3155; Fax: 61 8 8204 5114; Email:

john.miners@flinders.edu.au

Number of text pages: 30

Number of Tables: 4

Number of Figures: 5

Number of References: 33

Number of words in Abstract: 216

Number of words in Introduction: 610

Number of words in Discussion: 1495

Abbreviations: DTIC, dacarbazine (5-(3,3-dimethyl-triazenyl)-imidazole-4-carboxamide); CYP1A1, cytochrome P450 1A1; CPR, cytochrome P450 NADPH oxidoreductase; GDEPT, Gene Directed Enzyme Prodrug Therapy.

2

Abstract

The chemotherapeutic prodrug dacarbazine (DTIC) has limited efficacy in human malignancies and exhibits numerous adverse effects that arise from systemic exposure to the cytotoxic metabolite. DTIC is activated by CYP1A1 and CYP1A2 catalyzed N-demethylation. However, structural features of these enzymes that confer DTIC N-demethylation have not been characterized. A validated homology model of CYP1A1 was employed to elucidate structure-activity relationships and to engineer CYP1A1 enzymes with altered DTIC activation. In silico docking demonstrated that DTIC orientates proximally to S122, F123, D313, A317, I386, Y259, and L496 of human CYP1A1. The site of metabolism is positioned 5.6Å from the heme iron at an angle of 105.3º. Binding in the active-site is stabilized by H-bonding between Y259 and the N2 position of the imidazole ring. Twenty-seven CYP1A1 mutants were generated and expressed in *E. coli* in yields ranging from 9 to 225 pmol P450/mg. DTIC N-demethylation by the E161K, E256K, and I458V mutants exhibited Michaelis-Menten kinetics, with decreases in K_m (183 to 249 μM) that doubled the catalytic efficiency ($p < 0.05$) relative to wild-type CYP1A1 (K_m 408 ± 43 μM; V_{max} 28 ± 4 pmol/min/pmol P450). The generation of enzymes with catalytically enhanced DTIC activation highlights the potential use of mutant CYP1A1 proteins in P450-based gene-directed enzyme prodrug therapy (GDEPT) for the treatment of metastatic malignant melanoma.

Introduction

The chemotherapeutic prodrug dacarbazine (DTIC; Figure 1) is the most effective single agent used for the treatment of malignant melanoma. However, a beneficial response to DTIC treatment only occurs in approximately 19% of patients (Luce et al., 1970). During the past twenty years, all compounds in phase-III clinical trials targeted to treat metastatic melanoma have failed to improve patient outcomes compared to DTIC (Erdmann, 2010). DTIC requires metabolic activation by cytochromes P450 1A1, 1A2 and, to a much lesser extent, CYP2E1 for cytotoxicity (Reid et al., 1999). The main metabolic pathway involves α-hydroxylation of one of the *N*-methyl groups by the P450 enzymes to form 5-(3-hydroxy-methyl-3-methyl-triazen-1-yl)-imidazole-4-carboxamide (HMMTIC) (Figure 1). This metabolite is chemically unstable, losing formaldehyde to generate the *N*-demethylated species, 5-(3-methyl-triazen-1-yl)-imidazole-4-carboxamide (MTIC) (Rooseboom et al., 2004; Sanada et al., 2004). Rapid decomposition of MTIC yields 5-aminoimidazole-4-carboxamide (AIC), the major metabolite detected in plasma and urine, and the reactive species methane diazohydroxide, which produces molecular nitrogen and the methyl cation responsible for the formation of *O*-alkylguanine-DNA adducts (Meer et al., 1986).

Efforts to improve DTIC activation have focused on the development of new chemical analogues such as temozolomide (Stevens et al., 1987). However, like DTIC the activated metabolite requires transfer to the tumor via the circulation, thus resulting in systemic exposure. Containment of the cytotoxic metabolites in the tumor environment would potentially reduce the adverse effects experienced by patients during conventional chemotherapy with DTIC. As a targeted approach to chemotherapy, gene directed enzyme prodrug therapy (GDEPT) (Aghi et al., 2000; Cass et al., 2001; Daly, 2003; Denny, 2002; Hughes et al., 2002; Xu and McLeod,

2001) offers a strategy to improve tumor/drug selectivity in the treatment of cancer. GDEPT functions by localizing activation of a systemically administered prodrug by utilizing the expression of an exogenous drug-activating enzyme targeted to the tumor environment. The gene(s) encoding the enzyme(s) should be of human origin to alleviate adverse immune responses, and should be expressed in negligible levels throughout the body to avoid non-specific formation of the cytotoxic metabolite (Denny, 2002). The protein must achieve sufficient expression in the tumors and have high catalytic efficiency (Daly, 2003). Although the results from preclinical trials are encouraging with respect to the vectors and promoters utilized for gene expression (Kan et al., 2001; Lohr et al., 2001), improvements in the efficiency of the therapeutic enzymes utilized in GDEPT is still required.

An understanding of the structural organization and chemical interactions between P450 enzymes and their respective substrates is pivotal for characterizing structure-activity relationships. In the absence of a human CYP1A1 crystal structure, structure-activity analyses have been essential in understanding the mechanisms responsible for the substrate selectivity, regioselectivity, and stereoselectivity of this enzyme (Ericksen and Szklarz, 2005; Lewis, 2003; Lewis et al., 2002; Lewis et al., 2004; Liu et al., 2004; Miles et al., 2000; Ridderstrom et al., 2001; Schwarz et al., 2004). More recently, targeted mutagenesis experiments have been directed by *in silico* approaches based on the X-ray crystal structures of the human P450 enzymes. In a previous study, we utilized the human CYP1A2 X-ray crystal coordinates as a structural template for generating a chemically and energetically valid CYP1A1 homology model (Lewis et al., 2007). The predictivity of the CYP1A1 model was confirmed using directed mutagenesis which identified the active-site residues responsible for the productive orientation and binding of 7-ethoxyresorufin.

MOL #72124

Here, the CYP1A1 homology model was employed to direct the structural

modification of this enzyme to increase its catalytic efficiency (V_{max}/K_m) for DTIC *N*-

demethylation and subsequent activation. It was demonstrated that the E161K,

V228T, E256K, and I458V substitutions in human CYP1A1 enhance activation of

DTIC via the *N*-demethylation pathway, primarily by decreasing the K_m for this

reaction.

MOL #72124

Materials and Methods

Chemicals and Reagents

Restriction enzymes were purchased from New England Biolabs, Inc. (Hetfordshire, UK), dacarbazine (DTIC) and 5-aminoimidazole-4-carboxamide (AIC) from Sigma-Aldrich (Sydney, NSW, Australia), and *E. coli* DH5α cells from Life Technologies (Melbourne, VIC, Australia). Gel purified oligonucleotides were supplied by Sigma-Genosys (Sydney, NSW, Australia), Pfu Ultra HS II Polymerase by Stratagene (La Jolla, CA, USA), and Shrimp Alkaline Phosphatase (SAP) by Roche Diagnostics GmbH (Penzberg, Germany). All other chemicals and reagents were of analytical grade and purchased from Sigma-Aldrich unless otherwise stated.

In silico modeling to identify sites for targeted mutagenesis

Homology models containing mutations were constructed using the wild-type CYP1A1 homology model generated previously (Lewis et al., 2007). Targeted residues were mutated in silico, incorporating the desired amino acid. Each substituted residue was energy minimized as a subset of the entire protein molecule using the Powell conjugate gradient method with an energy cutoff set to 0.05 kcal/mol.Å. A 'hot region' of 6Å surrounding the substituted residue was established where the side-chains of all residues were minimized. A further 'intermediate region' of 12Å was generated to set the minimization environment without side-chain movement. Minimization by this method allowed changes in the energetic forces experienced by residues that either adjoin or neighbor the substituted amino acid.

Automated docking was achieved using the FlexX docking suite (SYBYL7.3, Tripos™). Docking of the ligand was consensus scored (CScore) based on its

7

interactions with the protein and the key residues involved in binding and orientation of DTIC in the protein active-site. Distance and angle data were collected to characterize the orientation of docked substrate poses. Distances were measured between the α-carbon of the substrate (i.e. the site of hydroxylation that precedes demethylation) and the heme iron. Angles (θ) were between the N1 atom of the heme pyrrole proximal to the I-helix, the heme iron, and the α-carbon of the substrate. Active-site residues involved in the binding and orientation of DTIC were targeted based on their proximity to the docked DTIC molecule generated *in silico*. Residues within a 3Å radius whose side-chain chemistry interacted with the docked substrate were considered for mutagenesis. In addition, residues able to affect the electrostatic environment surrounding the heme, the reductase binding domain, and residues potentially involved in the metabolism of heterocyclic amines in rat CYP1A1 were targeted. All substitutions were guided by consideration of the importance of the side-chain functional group(s) and how they contribute to substrate alignment, orientation, and enzyme function.

CYP1A1 and CPR cDNAs, and generation of CYP1A1 mutants

N-Terminus modifications previously shown to promote high levels of bacterial expression of human P450s were made to the wild-type CYP1A1 cDNA (GenBank accession no. NM_000499) as described previously (Lewis et al., 2007). *NdeI* and *XbaI* restriction sites (shown in italics) were additionally incorporated for cloning purposes: forward primer, 5′ AT*CATATG*ATCATGGCTCTGTTATTAGCAGTTTTTCTGTTCTGTCTGG 3′; reverse primer, 5′ TA*TCTAGA*ACCTAGTGATGGTGATGGTGATGAGAG

CGCAGCTGCATTTGG 3′. The 1551bp PCR product was ligated into the pCW ori(+) plasmid and transformed into DH5α *E. coli* cells. The CPR expression construct, generated using the bacterial plasmid pACYC, comprised the OmpA signal sequence fused upstream of the full length native rat CPR sequence (Shen et al., 1989).

The CYP1A1 residues S116, S122, F123, E161, E166, V191, F224, V228, E256, Y259, N309, L312, D313, G316, A317, D320, T321, V322, I386, I458, and T497 were mutated to generate 116A, 122A, 122T, 123A, 161K, 166Q, 191M, 224A, 228T, 256K, 259F, 309T, 312F, 313A, 313N, 316V, 317G, 317Y, 320A, 321G, 321P, 321S, 322A, 386G, 386V, 458P, 458V, and 497S variants. Supplemental data (video 1) displays all sites of mutagenesis relative to the tertiary structure of human CYP1A1. Due to the high GC content of the CYP1A1 cDNA the primer design method described by Zheng et al. (2004) was used to minimize primer hetero-dimerization. The partially overlapping primers used for mutagenesis are given in Table 1; cycling parameters were as described elsewhere (Lewis et al., 2007). Mutations were confirmed by nucleotide sequencing on both strands (ABI 3130-XL DNA sequencer, Applied Biosystems, Victoria, Australia).

Heterologous co-expression of P450s and CPR

The wild-type pCW 17α-CYP1A1 and all CYP1A1 mutant (Table 1) cDNAs were individually transformed into DH5α *E. coli* cells that were stably transformed with the pACYC OmpA-rCPR construct as previously described (Lewis et al., 2007). Cells cultured overnight (5 mL) in Luria-Bertani broth with ampicillin (100 μg/mL) and chloramphenicol (10 μg/mL) at 37ºC were used to inoculate 100 mL cultures of

Terrific broth containing 100 µg/mL ampicillin, 10 µg/mL chloramphenicol, and rare elements solution (25 µM $FeCl_3.6H_2O$, 2 µM $ZnCl_3.4H_2O$, 2.5 µM $CaCl_2.6H_20$, 2.5 µM Na_2MoO_4, 1.7 µM $CaCl_2.2H_2O$, 1.85 µM $CuCl_2$, 2 µM H_3BO_3, 30 µM HCl). Cultures were grown at 37ºC with shaking (160 rpm) for 4 h, or until reaching an optical density of 0.7 to 0.9 AU at 600 nm. After cooling to 26ºC, cultures were induced with isopropyl-1-thio-β-D-galactopyranoside (1 mM) and δ-aminolevulinic acid (1 mM) and then grown at 26ºC with shaking (160 rpm) for an additional 64 h in <1% dissolved oxygen. Membrane fractions were prepared according to Gillam et al. (1993) and stored in aliquots at -80°C. Protein concentrations were determined using the method of Lowry et al. (1951). Total P450 content and CPR activity were measured spectrophotometrically (Omura and Sato, 1964a; Omura and Sato, 1964b; Yasukochi and Masters, 1976).

Measurement of DTIC *N*-demethylation activity

AIC formation was determined in opaque glass tubes at 37ºC in a total incubation volume of 0.2 mL. Incubation mixtures contained co-expressed CYP1A1 (5.0 pmol) and CPR (5 to 160 pmol), NADPH generating system (1 mM $NADP^+$, 10 mM glucose-6-phosphate, 2 IU glucose-6-phosphate dehydrogenase, 5 mM $MgCl_2$) and DTIC (100-6000 µM) in phosphate buffer (0.1M, pH 7.4). Following a 5 min pre-incubation at 37ºC in a shaking water bath, reactions were initiated by the addition of NADPH generating system. Incubations were terminated after 60 min by the addition of 2 µL of ice cold 70% perchloric acid. Reaction mixtures were vortex mixed, cooled on ice for 10 min, centrifuged (5000x *g* for 10 min at 4ºC), and an aliquot of the supernatant fraction (20 µL) injected onto the HPLC column.

DTIC stock solutions were prepared as a 1:1 molar ratio of HCl in water and protected from light. Dilutions of the DTIC stock solutions were confirmed by HPLC to ensure linearity; r^2 values were >0.991. Samples were prepared by diluting 1:100 with mobile phase and an aliquot (4 μL) injected onto the HPLC column and separated using a mobile phase comprising 80% A and 20% B (see below). Elution was monitored by UV detection at 267 nm. The retention time of DTIC was 1.4 min at a mobile phase flow rate of 1 mL/min.

Measurement of AIC formation

AIC was separated using a Waters Nova-Pak® C18 column (150 x 3.9 mm, 4 μm; Waters Corporation, MA, USA) consisting of mobile phase (A) 10 mM heptane sulfonic acid, 5% (v/v) acetonitrile, and 0.1% (v/v) triethylamine, adjusted to pH 3.0 with 85% orthophosphoric acid (filter sterilized; 0.45 μm) and mobile phase (B) acetonitrile (100%). The following mobile phase gradient was used to elute AIC: 100% A held for 5.1 min, then changed to 70% A/30% B over 0.7 min, and held for 0.1 min, followed by returning to 100% A over 0.1 min and held for 5.1 min. AIC was monitored by UV detection at 267 nm. The retention time of AIC was 5.2 min using a mobile phase flow rate of 1 mL/min. Unknown concentrations of AIC were determined by comparison of the peak area to a calibration curve constructed in the concentration range 2.5 to 100 μM.

Calculation of DTIC kinetic parameters

The rates of AIC formation versus substrate concentration (100-6000 μM) were model-fitted using the non-linear curve fitting program EnzFitter (Biosoft,

Cambridge, UK). Kinetic constants (K_m, V_{max}, n, and S_{50}) for AIC formation were derived from fitting either the Michaelis-Menten equation or the Hill equation to experimental data. Goodness of fit was assessed from the F-statistic, 95% confidence intervals, r^2 value, and standard error of the parameter fit. Statistical analysis (multivariate general linear model; Tukey *post hoc*) was undertaken using PASW Statistics version 18.0 (SPSS Inc. Chicargo, USA). Kinetic data are given as the mean ± SD of four separate experiments with values of $p < 0.05$ considered significant.

Results

Automated docking of DTIC

DTIC was docked into the CYP1A1 active-site using the homology model generated previously in this laboratory (Lewis et al., 2007). The energetically favored pose of DTIC places the α-carbon of the side-chain *N*-methyl at 5.6Å from the iron at an angle of 105.3º perpendicular to the plane of the heme (Figure 2A). This measurement is dependant on free rotation about the *N*-dimethyl side-chain of the triazene of DTIC. Binding and orientation of DTIC within the active-site involves I115, S120, S122, F123, F224, F258, Y259, D313, G316, A317, I386, and L496, with all twelve residues positioned within a 3Å radius from DTIC (Figure 2B). Van der Waals forces between enzyme and substrate suggest significant interactions with S122, F123, D313, A317, I386, Y259, and L496. H-bonding can occur between the oxygen of S122 and the triazene N6 nitrogen of DTIC. However, based on the speciation of DTIC at pH 7.4, H-bonding at this location is unlikely unless the active-site pH drops below 4 during substrate binding or catalysis. Further H-bonding is observed between the hydroxyl hydrogen of Y259 and the N2 aromatic nitrogen of the imidazole ring, which is likely to occur in all substrate molecules at physiological pH. Edge-to-face and parallel displaced aromatic interactions are predominant with F123, and F224, F258, and Y259 respectively (Figure 2B). The free rotation of the *N*-dimethyl substituent of DTIC appears dependant on the size of residues located at positions 317 (I-helix; SRS 4) and 386 (K-helix/β2-3 loop; SRS5). Residue 317 is a small nonpolar aliphatic alanine and residue 386 is a C β-branched nonpolar aliphatic isoleucine. These two residues constrain the width of the catalytic cleft of the active-site to 5.4Å. Aspartate 313 is in close proximity to the aromatic nitrogen closest to the triazene

substituent. At pH 7.4 this nitrogen is negatively charged in 97% of DTIC molecules.

Thus, strong charge interactions contributed by D313 may affect the orientation of

DTIC in the CYP1A1 active-site.

Mutant CYP1A1 enzymes

Structural models were built to assist interpretation of the mutagenesis data. Table 2

displays the angle and distance data for DTIC docked in silico for each mutant

orientated for productive *N*-demethylation. The root mean squared deviation (RMSD)

of each mutant was calculated relative to the wild-type model to identify structural

differences. Substitutions generating the greatest structural deviations relative to wild-

type are represented by large RMSD values. Of particular interest were RMSD values

for S116A, F224A, V228T, Y259F, and T497S, which show structural deviations are

dependant on amino acid chemistry (i.e. polar, aliphatic, aromatic, charge state) and

the spatial orientation of residues relative to neighboring amino acids (Table 2).

Heterologous co-expression of P450s

Wild-type CYP1A1 and mutant CYP1A1 enzymes were individually co-expressed

with CPR. The expression of holo-enzyme achieved in *E. coli* (n ≥ 3 experiments),

estimated from the carbon monoxide difference spectrum, varied between each

enzyme. Expression data are given in Table 3. Levels of expression ranged from 9 to

225 pmol P450/mg protein. With the exception of E166Q, all mutants that expressed

less than 50 pmol P450/mg protein are located in the protein active-site. Levels of co-

expressed CPR varied to a lesser extent, with a mean yield of 292 ± 64 pmol

reductase/mg protein (n > 60 experiments). As noted in 'Materials and Methods', the

MOL #72124

P450:CPR ratio for the wild-type CYP1A1 and all CYP1A1 mutants was in the range of 1:1 to 1:32 which is expected to provide sufficient reductase for efficient catalysis.

Effects of CYP1A1 mutations on DTIC activation

Wild-type CYP1A1 and mutant CYP1A1 enzymes were characterized for DTIC *N*-demethylase activity, measured as AIC formation, to generate kinetic parameters (Table 4). With the exception of the I386G mutant, all enzymes catalyzed DTIC *N*-demethylation. The CYP1A1 mutants S122A, S122T, F123A, E166Q, D313A, D313N, T321G, T321P, T321S, and T497S displayed negative cooperative kinetics and data were modeled using the Hill equation. Wild-type CYP1A1 and the remaining CYP1A1 mutants displayed hyperbolic rate plots and data were well described by the Michaelis-Menten equation. It should be noted that binding of DTIC to *E. coli* membranes is < 5%. Thus, variation in non-specific binding between incubations does not account for the differences in kinetics (and kinetic parameters) observed for the CYP1A1 mutants.

Figure 3 shows representative Eadie-Hofstee plots for DTIC *N*-demethylation by wild-type CYP1A1 and the E161K, V228T, E256K, I386V, and I458V mutants. The kinetic parameters for DTIC *N*-demethylation by wild-type CYP1A1 (V_{max} 28 $\pm$ 4 pmol/min/pmol P450, K_m 408 $\pm$ 43 μM) are in reasonable agreement with the only other CYP1A1 data available for this substrate; V_{max} 10.2 $\pm$ 2.1 pmol/min/pmol P450 and K_m 595 $\pm$ 111 μM (Reid et al., 1999). The E161K, E256K, and I458V substitutions all resulted in an approximate two-fold increase in binding affinity (i.e. decrease in K_m) with no change in V_{max}, thereby doubling catalytic efficiency (CL_{int}) (p < 0.05). The V228T mutant exhibited an elevated V_{max} generating a 23% increase

15

in CL_{int}. While there were significant increases in both V_{max} and K_m of the I386V mutant ($p < 0.05$), there was no overall change in CL_{int} ($p = 0.872$).

CL_{int} values for all other mutants were lower than for wild-type CYP1A1. Rate versus substrate concentration and Eadie-Hofstee plots for these mutants are provided as supplementary data (Figure S1). Interestingly, ten of the mutations resulted in a change from the hyperbolic kinetics observed for wild-type CYP1A1 to negative cooperative kinetics (Table 4 and Figure S1).

Kinetic and structural analysis of DTIC activation by CYP1A1 enzymes

With the exception of F123A, D313N, and T321G mutants, V_{max} values for DTIC N-demethylation (measured as AIC formation) were either equivalent to or greater than wild-type (Table 4). However, profound effects on K_m/S_{50} were observed for a number of mutants, in particular S122A, F123A, E166Q, D313A, D313N, G316V, A317G, T321P, and T321S (Table 4). The derived S_{50} value for the S122A mutant was very high, most likely due to the mis-alignment of DTIC in the CYP1A1 active-site, which is also due in part to the aromatic and polar interactions contributed from Y259 (Figure 4A). Substitution to threonine (S122T) resulted in a smaller increase in S_{50} (Table 4), suggesting that the polar nature of residue 122 contributes significantly to binding affinity. Data obtained for the F123A mutant revealed decreases in both V_{max} and substrate binding affinity, most likely due to substrate destabilization caused by the loss of edge-to-face electrostatic interactions (Figure 4B). The decrease in binding affinity observed for the E166Q substitution may arise from effects on efficient electron transfer as this residue is located in the D-helix on the outer surface of CYP1A1 (Supplementary video V1) and may influence the interaction between

CYP1A1 and CPR (Figure 4C). The D313A and D313N mutants exhibited similar increases in S_{50}. Substrate binding affinity is presumably reduced due to the altered charge; negative to neutral at physiological pH. However, whereas replacement of the charged aspartate with asparagine significantly decreased V_{max} (Figure 4D), substitution with alanine resulted in a small increase in this parameter relative to wild-type. Residues 316 and 317 are located in the I-helix (Figure 4E). The G316V and A317G substitutions alter the volume of the active-site and impact on the optimal alignment of DTIC for productive *N*-demethylation. Both substitutions alter conformation of the I-helix, but there is a more substantial effect on substrate binding affinity from removal of the side-chain at residue 317 (A317G).

Residue 321 is located in the I-helix and is highly conserved (96.6%) among human P450 enzymes (Figure 4F). Threonine 321 is believed to facilitate proton transport during catalysis by aligning water in the 'proton transfer groove' (Haines et al., 2001; Lewis et al., 2004). The decrease in activity observed for the T321G mutant may arise from altered conformational flexibility in the I-helix and/or effects on the alignment of water in the active-site. Glycine and serine substitutions at residue 321 relieve the restricted secondary structure due to the β-branched side-chain of threonine in the wild-type enzyme. In the case of the T321P mutant, the restricted geometry ($\psi = -75°$) ensures that this residue behaves as a β-branched amino acid, with a substantial impact on substrate binding affinity.

Discussion

Although DTIC has relatively poor clinical activity and results in numerous adverse effects, it is still the most effective single agent used for the treatment of metastatic malignant melanoma (Erdmann, 2010). While the pharmacology of DTIC is well understood, only a single study has investigated the metabolism of DTIC by cytochromes P450 (Reid et al., 1999). Given DTIC requires metabolic activation by P450's for cytotoxicity, an opportunity exists to utilize mutant enzymes with enhanced DTIC activation for potential use in P450-based GDEPT strategies.

Docking studies revealed DTIC orientates in close proximity to S122, F123, D313, A317, I386, Y259, and L496 (Figure 2B). The energetically favorable pose placed the carbon that is hydroxylated 5.6Å from the heme catalytic site, with H-bonding occurring between Y259 and the aromatic nitrogen of the imidazole ring (Figure 2A and B). In addition to Y259, H-bonding interactions of mutant enzymes occurred at positions 122, 313, and 316, and were dependant on the type of amino acid substituted. Interestingly, the energetically favored orientation of DTIC in the E256K mutant revealed H-bonding not only from N2 of the imidazole but also from the carboxamide to Y259. Based on the predictivity of the CYP1A1 model (Lewis et al., 2007), DTIC binding and orientation was assessed with mutants generated in silico. All mutants were designed to alter the *N*-demethylation of DTIC by manipulating steric, polar, aromatic, or electrochemical interactions.

To determine the affect of each mutation on the conversion of DTIC to AIC (via *N*-demethylation), the co-expression of recombinant CYP1A1 proteins with CPR was achieved using an optimized method that increased yield 7-fold compared to literature reports (Table 3). All enzymes catalyzed DTIC *N*-demethylation except for the I386G

mutant, despite the presence of holo-P450. The lack of both DTIC *N*-demethylation and 7-ethoxyresorufin *O*-deethylation (Lewis et al., 2007) suggests flexibility in the K-helix/β2-3 loop may impact on the substrate access channel/active-site boundary. The CYP1A1 computational model identified that F123 relaxes into a void in the CYP1A1 substrate access channel generated by the I386G mutant. The aromatic side-chain of F123 pivots inwards toward the heme prosthetic group by 25.4°. Although the distance between F123 and I386 in the wild-type protein (3.1Å) is the same as that between F123 and G386 in the mutant, the decrease in side-chain size (-2.2Å) and loss of β-branching results in constriction at the CYP1A1 substrate access channel/active-site boundary. Proline 387 is similarly affected by the glycine substitution in the I386G mutant, resulting in disruption of the architecture of the substrate-access channel. However, this effect is not sufficient to hinder heme incorporation during protein folding or the access of $CO_{(g)}$.

The kinetics of AIC formation (via DTIC *N*-demethylation) by CYP1A1 was well modeled using the Michaelis-Menten equation (Figure 3). DTIC *N*-demethylation by the E161K, E256K, and I458V mutants similarly exhibited Michaelis-Menten kinetics, with lower K_m values that resulted in a doubling of catalytic efficiencies (Table 4). The V228T mutant increased catalytic efficiency relative to the wild-type enzyme by 23%. The mechanism(s) associated with the altered substrate binding affinity differs for each of these high-activity mutants. While it is difficult to elucidate structure-activity relationships for the E161K mutant since this residue resides on the surface of the protein (Figure 4A; Supplementary video V1), the substitution of glutamate for lysine results in a reversal in charge-state of the substituted amino acid, with a change in protonation at physiological pH. It is believed that residue 161 is involved in CPR binding (Parikh et al., 1999). Thus, the localized charge effects seen

with the E161K substitution may aid a more complementary alignment of CPR via salt-bridge formation. For the E256K mutant, localized charge effects enhance H-bonding to D253 (Figure 5). Of particular interest were modifications in the side-chain orientations of F258 and Y259, which impact on DTIC alignment over the heme catalytic site. The decrease in K_m obtained with the I458V mutant apparently results from realignment of the heme prosthetic group. Preservation of Cβ-branching maintains the rigid conformation of the β4-2/L-helix loop and improves activity (Table 4).

Although the primary focus of this study was to generate CYP1A1 enzymes with enhanced DTIC *N*-demethylase activities (measured as AIC formation), data obtained for other mutants contribute to the overall understanding of CYP1A1 structure-activity relationships. While the S122A, D313A, and T321S mutants showed higher V_{max} values for DTIC *N*-demethylation compared to wild-type CYP1A1, there were large decreases in binding affinity (assessed as S_{50}) (Table 4 and Figure S1). In addition, all three mutants exhibited negative cooperative kinetics. Interestingly, a doubling in V_{max} and reduction in binding affinity was similarly observed for 7-ethoxyresorufin *O*-deethylation by S122A (Lewis et al., 2007). Docking studies with 7-ethoxyresorufin identified that hydrogen bonding of the oxazine ring oxygen to residue 122 was disrupted in the S122A mutant resulting in a productive binding orientation where hydrogen bonding occurs between the phenoxazine carbonyl of 7-ethoxyresorufin and the hydroxyl oxygen of Y259. The D313A substitution in this study is expected to produce significant effects on the volume and topology of the active-site, and the loss of charge associated with aspartic acid will influence interactions with neighboring residues. While residues 122 and 313 are sufficiently distal to the catalytic heme iron to have no direct impact on reaction mechanism, they

do alter the optimal alignment and orientation of the substrate for productive hydroxylation (Table 2). In contrast, residue 321 is located in the I-helix adjacent to the heme and is known to influence catalysis. Thus, V_{max} depends on the amino acid substitution; data obtained for T321G, T321P, and T321S support this notion (Table 4). In particular, substitution with the polar serine (T321S) doubled the V_{max} for DTIC *N*-demethylation, presumably by facilitating proton transfer (Table 4) whereas the T321G substitution resulted in a markedly reduced V_{max} relative to wild-type. The latter observation is consistent with previous data from this laboratory with 7-ethoxyresorufin as substrate (Lewis et al., 2007).

Perturbations in the simultaneous 'coming together' and ideal geometric alignment of substrate, molecular oxygen, water, and the heme iron, lead to altered productivity in P450 enzymes. Thus, mutagenesis of active-site residues directly impact on substrate orientation and catalytic efficiency. However, less obvious is the effects of disruption to the normally ordered packing of water molecules in the active-site which, similar to substrate, occur in parallel with the modification of active-site residues. In order for catalysis to proceed in proteins with an altered arrangement of water, substrate binding in an 'open state' conformation may be required for efficient proton delivery to the iron-dioxygen intermediate. Since the kinetic model for negative cooperativity does not distinguish between the simultaneous binding of multiple substrate molecules within a single active-site or the binding of two substrate molecules to two distinct binding sites (Houston and Galetin, 2005), it might be speculated that the negative cooperative kinetics observed for some mutant CYP1A1 enzymes arises from an energetically unfavored 'open' conformation which subsequently allows the binding of a second substrate molecule, either within the active-site or at another distinct binding site. This effect may be more prominent in P450 enzymes with small

active-site cavities, such as CYP1A1 ($\sim339\text{Å}^3$), which in a catalytically 'closed' conformation can only accommodate a single substrate molecule in the active-site. Interestingly, in silico docking experiments show binding of a second DTIC molecule is permitted within the substrate access-channel due to interactions with V228, N232, S247, and F251 (data not shown). Whether the 'atypical' (i.e. non Michaelis-Menten) DTIC kinetics observed here for several of the CYP1A1 mutants arises from binding within the substrate access-channel or from another mechanism is yet to be established.

As noted above, it is well established that mutation of amino acids within a 3Å radius of bound substrate is likely to affect catalytic efficiency. However, more subtle manipulation of amino acids may also enhance the catalytic activity of an enzyme-substrate pair. It is evident from data presented here that side-chain reorientation of the native active-site residues can be introduced by the mutagenesis of residues outside of the active-site, and this may be achieved by consideration of the physicochemical, bonding, and folding interactions of the amino acid targeted for substitution and with the residue(s) within the active-site. This process, which is also dependant on the chemical and physicochemical features of the substrate, can be facilitated by the use of a validated homology model generated from crystal templates of high quality and homology (in this case CYP1A1 and CYP1A2) and should therefore translate to other enzyme-substrate combinations. Application of the CYP1A1 homology model in this study has provided insights into the mechanism of altered kinetic parameters for DTIC *N*-demethylation. The homology model does not, however, provide a clear explanation for the negative cooperative kinetics associated with a number of the mutants.

In conclusion, this study has demonstrated that E161K, V228T, E256K, and I458V substitutions in human CYP1A1 can enhance the catalytic efficiency of DTIC activation via the *N*-demethylation pathway. The combination of kinetic analyses with in silico docking has permitted interpretation of the structure-activity relationships of this enzyme-substrate pair, highlighting the importance of electrostatic and charge interactions. The improved understanding of DTIC activation by CYP1A1 provides a potential strategy for CYP1A1-based GDEPT for the treatment of metastatic malignant melanoma.

MOL #72124

Authorship Contributions

Participated in research design: Lewis, Mackenzie, Miners

Conducted experiments: Lewis

Wrote or contributed to the writing of the manuscript: Lewis, Mackenzie, Miners

References

Aghi M, Hochberg F and Breakefield XO (2000) Prodrug activation enzymes in cancer gene therapy. J Gene Med 2(3):148-164.

Cass CE, Young JD, Baldwin SA and Baldwin A (2001) Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Molec Membrane Biol 18(1):53-63.

Daly AK (2003) Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundamental Clin Pharmacol 17(1):27-41.

Denny WA (2002) Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy). J Biomed Biotechnol 2003(1):48-70.

Erdmann MK (2010) Immunity unleashed in melanoma. Lancet Oncology 11(2):108-109.

Ericksen SS and Szklarz GD (2005) Regiospecificity of human cytochrome P450 1A1-mediated oxidations: The role of steric effects. J Biomol Struct Dyn 23(3):243-256.

Haines DC, Tomchick DR, Machius M and Peterson JA (2001) Pivotal role of water in the mechanism of P450BM-3. Biochemistry 40(45):13456-13465.

Houston JB and Galetin A (2005) Modelling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 433(2):351-360.

Hughes TL, Johnson T, Razzano LA, Cassidy R and Ferguson MJ (2002) The role of pro-drug therapy in the treatment of cancer. Am J Public Health 92(7):1131-1139.

Kan O, Griffiths L, Baban D, Iqball S, Uden M, Spearman H, Slingsby J, Price T, Esapa M, Kingsman S, Kingsman A, Slade A and Naylor S (2001) Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Therapy 8(7):473-482.

Lewis BC, Mackenzie PI and Miners JO (2007) Comparative homology modeling of human cytochrome P4501A1 (CYP1A1) and confirmation of residues involved in 7-ethoxyresorufin O-deethylation by site-directed mutagenesis and enzyme kinetic analysis. Arch Biochem Biophys 468(1):58-69.

Lewis DF (2003) Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys 409(1):32-44.

Lewis DF, Modi S and Dickins M (2002) Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev 34(1-2):69-82.

Lewis DFV, Lake BG and Dickins M (2004) Quantitative structure-activity relationships within a homologous series of 7-alkoxyresorufins exhibiting activity towards CYP1A and CYP2B enzymes: molecular modelling studies on key members of the resorufin series with CYP2C5-derived models of human CYP1A1, CYP1A2, CYP2B6 and CYP3A4. Xenobiotica 34(6):501-513.

Liu J, Ericksen SS, Si vaneri M, Besspiata D, Fisher CW and Szklarz GD (2004) The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism. Arch Biochem Biophys 424(1):33-43.

Lohr M, Hoffmeyer A, Kroger JC, Freund M, Hain J, Holle A, Karle P, Knofel WT, Liebe S, Muller P, Nizze H, Renner M, Saller RM, Wagner T, Hauenstein K,

Gunzburg WH and Salmons B (2001) Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 357(9268):1591-1592.

Lowry OH, Rosenbrough NJ, Farr L and Randall RJ (1951) Protein Measurement with the Folin Phenol Reagent. J Biol Chem 193:267-275.

Luce J, Thurman WG, Isaacs BL and Talley RW (1970) Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388). Cancer Chemother Rep 54(2):119-124.

Meer L, Janzer RC, Kleihues P and Kolar GF (1986) In vivo metabolism and reaction with DNA of the cytostatic agent, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC). Biochem Pharmacol 35(19):3243-3247.

Miles CS, Ost TWB, Noble MA, Munro AW and Chapman SK (2000) Protein engineering of cytochromes P-450. Biochim Biophys Acta-Protein Struct Molec Enzym 1543(2):383-407.

Omura T and Sato R (1964a) The carbon monoxide-binding pigment of liver microsomes: Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.

Omura T and Sato R (1964b) The carbon monoxide-binding pigmentof liver microsomes. J Biol Chem 239(7):2379-2385.

Parikh A, Josephy PD and Guengerich FP (1999) Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties. Biochemistry 38(17):5283-5289.

Reid JM, Kuffel MJ, Miller JK, Rios R and Ames MM (1999) Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res 5(8):2192-2197.

Ridderstrom M, Zamora I, Fjellstrom O and Andersson TB (2001) Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. J Med Chem 44(24):4072-4081.

Rooseboom M, Commandeur JNM and Vermeulen NPE (2004) Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56(1):53-102.

Sanada M, Takagi Y, Ito R and Sekiguchi M (2004) Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations. DNA Repair 3:413-420.

Schwarz D, Kisselev P, Ericksen SS, Szklarz GD, Chernogolov A, Honeck H, Schunck WH and Roots I (2004) Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid. Biochem Pharmacol 67(8):1445-1457.

Shen AL, Porter TD, Wilson TE and Kasper CB (1989) Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis. J Biol Chem 264(13):7584-7589.

Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW and Slack JA (1987) Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47(22):5846-5852.

Xu G and McLeod HL (2001) Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res 7(11):3314-3324.

Yasukochi Y and Masters BS (1976) Some properties of a detergent-solubilized NADPH-cytochrome c(cytochrome P-450) reductase purified by biospecific affinity chromatography. J Biol Chem 251(17):5337-5344.

Zheng L, Baumann U and Raymond JL (2009). An efficient one-step site-directed and site-saturation mutagenesis protocol. Nucl Acids Res 32(14), e115.

MOL #72124

Footnote

Grant funding from the National Health & Medical Research Council of Australia and

the Faculty of Health Sciences of Flinders University is gratefully acknowledged.

Legends for Figures

Figure 1. Metabolic activation of dacarbazine (DTIC).

Figure 2. Orthogonal image of: (A) the α-carbon of the *N*-dimethyl substituent positioned in the energetically favored orientation for *N*-demethylation; and (B) key amino acids (lines) of CYP1A1 involved in the binding and orientation of DTIC (capped sticks). Secondary structure, grey (translucent); carbon atoms, black; nitrogen atoms, dark grey; hydrogen atoms, grey.

Figure 3. Eadie-Hofste plots for DTIC *N*-demethylation by: (A) wild-type CYP1A1, (B) CYP1A1-E161K, (C) CYP1A1-V228T, (D) CYP1A1-E256K, (E) CYP1A1-I386V, and (F) CYP1A1-I458V. Points show experimentally determined activities while lines are from model-fitting.

Figure 4. Structural orientations of key mutations: (A) CYP1A1-S122A/S122T , (B) CYP1A1-F123A, (C) CYP1A1-E166Q, (D) CYP1A1-D313A/D313N (E) CYP1A1-G316V/A317G, and (F) CYP1A1-T321G/T321P/T321S. Mutant residues (lines) are displayed relative to DTIC docked in the wild-type CYP1A1 structure (capped sticks). Secondary structure, grey (translucent); carbon atoms, black; nitrogen atoms, dark grey; hydrogen atoms, grey.

Figure 5. The E256K substitution modifies the side-chain orientation of F258 and Y259 (lines) which alters DTIC (capped sticks) alignment compared to the wild-type CYP1A1 enzyme (grey capped sticks). Secondary structure, grey (translucent); carbon atoms, black; nitrogen atoms, dark grey; hydrogen atoms, grey.

Table 1. Primers used for site-directed mutagenesis [a,b].

CYP1A1 mutant	Primer Overlap (5' forward to 5' reverse)	CYP1A1 mutant	Primer Overlap (5' forward to 5' reverse)
S116A	CCCTCATC*GC*TAATGGTCAGAGCATGTCC GTGGAAGTGGGAGTAG*CG*ATTACCAG	D313N	AGATCATTAACATCGTCTTG*A*ACCTCTTTGGAGCTGGG TCTAGTAATTGTAGCAGAAC*T*TGGAGAAACCTCGACCC
S122A	CAGAGCATG*G*CCTTCAGCCCAGACTCTGG GTCATTACCAGTCTCGTAC*C*GGAAGTCG	G316V	TCTTTG*T*AGCTGGGTTTGACACAG GCAGAACCTGGAGAAAC*A*TCGACCC
S122T	CAGAGCATG*A*CCTTCAGCCCAGACTCTGG GTCATTACCAGTCTCGTAC*T*GGAAGTCG	A317G	CTTTGGAG*G*TGGGTTTGACACAGTC GCAGAACCTGGAGAAACCTC*C*ACCCAAAC
F123A	GCATGTCC*GC*CAGCCCAGACTCTGGACC CATTACCAGTCTCGTACAGG*CG*GTCGGGTC	A317Y	TCTTTGGA*TA*TGGGTTTGACACAGTCAC GCAGAACCTGGAGAAACCT*AT*ACCCAAAC
E161K	CCTCAACCTCCTGCTACCTGGAA*A*AGCATGTGAGCAAGGAGG GGAGTTGGAGGACGATGGACCTTT*T*TCGTACACTCGTTCCTCC	D320A	GGTTTG*C*CACAGTCACAACTGCTATCTC CTGGAGAAACCTCGACCCAAAC*G*GTGTCAGTG
E166Q	GGAAGAGCATGTGAGCAAG*C*AGGCTGAGGTCCTGATAAGC CCTTCTCGTACACTCGTTC*G*TCCGACTCCAGGACTATTCG	T321G	GGTTTGAC*GG*AGTCACAACTGCTATCTCC GGAGAAACCTCGACCCAAACTG*CC*TCAGTGTTG
V191M	CTTTAACCCCTACAGGTATGTG*A*TGGTATCAGTGACCAATG GAAATTGGGGATGTCCATACACT*A*CCATAGTCACTGGTTAC	T321P	CTGGGTTTGAC*C*CAGTCACAACTGCTATCTCC CTGGAGAAACCTCGACCCAAACTG*G*GTCAGTG
F224A	GAATAATAAT*GC*CGGGGAGGTGGTTGGCTC GGATCAGTTGGACTTATTATTA*CG*GCCCCTCC	T321S	GGTTTGAC*T*CAGTCACAACTGCTATCTCC GGAGAAACCTCGACCCAAACTG*A*GTCAGTG
V228T	GGGAGGTG*AC*TGGCTCTGGAAACCCAGC CTTATTATTAAAGCCCCTCCAC*TG*ACCGAGAC	V322A	GACACAG*C*CACAACTGCTATCTCC CTCGACCCAAACTGTGTC*G*GTGTTGAC
E256K	ACCTGAAT*A*AGAAGTTCTACAGCTTC CGGAAGTTCCTGGACTTA*T*TCTTCAAG	I386G	CCTTCACC*GG*CCCCCACAGCACAACAAGAG GAAGGAAGCAGGGGAAGTGG*CC*GGGGGTGT
Y259F	GAAGTTCT*T*CAGCTTCATGCAGAAGATG GGACTTACTCTTCAAGA*A*GTCGAAG	I458P	GGGCAAGCGGAAGTGT*CC*CGGTGAGACCATTGCCCG CCCGTTCGCCTTCACA*GG*GCCACTCTGGTAACGGGC
N309T	GATCATTA*C*CATCGTCTTGGACCTCTTTGG CAGTCTACTCTTCTAGTAAT*G*GTAGCAGA	I458V	GGCAAGCGGAAGTGT*G*TCGGTGAGACCATTGCCCGC CGTACCCGTTCGCCTTCACA*C*AGCCACTCTGGTAACGGGCG
L312F	CATCGTCTTT*T*GACCTCTTTGGAGCTGGG CTAGTAATTGTAGCAGAA*A*CTGGAGAA	T497S	GGGCTA*T*CCATGAAGCATGCCTGC GGGGGTAGATACCCGATA*G*GTACTTC
D313A	CGTCTTGG*C*CCTCTTTGGAGCTGGGTTTGAC CTCTTCTAGTAATTGTAGCAGAACC*G*GGAGAAACC		

[a] Mutagenic nucleotides are highlighted in italics. [b] Wild-type CYP1A1 (Accession NM_000499) was used as the parent template to generate all mutants.

32

Table 2. Structural data of CYP1A1 mutants with docked DTIC orientated for productive *N*-demethylation.

Mutant	RMSD[a]	DTIC orientation[b]
S116A	0.1307	95.2°; 6.2Å
S122A	0.0287	99.7°; 5.5Å
S122T	0.0408	115.2°; 4.3Å
F123A	0.0739	114.6°; 4.8Å
E161K	0.0718	126.3°; 4.3Å
E166Q	0.0512	105.3°; 5.0Å
V191M	0.058	106.8°; 4.9Å
F224A	0.1327	106.0°; 4.7Å
V228T	0.0978	108.2°; 5.8Å
E256K	0.0680	95.4°; 6.8Å
Y259F	0.1174	120.4°; 4.0Å
N309T	0.0631	102.8°; 5.7Å
L312F	0.0652	92.2°; 6.5Å
D313A	0.0434	101.7°; 4.5Å
D313N	0.0678	122.6°; 4.1Å
G316V	0.0449	132.6°; 2.9Å
A317G	0.0297	111.7°; 4.5Å
D320A	0.0693	102.6°; 5.2Å
T321G	0.0525	124.5°; 3.8Å
T321P	0.0728	113.8°; 4.3Å
T321S	0.0212	110.8°; 5.0Å
V322A	0.0441	119.5°; 4.5Å
I386G	0.0326	115.5°; 4.9Å
I386V	0.0359	127.1°; 3.9Å
I458P	0.0362	112.2°; 4.5Å
I458V	0.0505	106.4°; 4.8Å
T497S	0.1016	123.4°; 4.7Å

[a] Root mean squared deviation (RMSD) is calculated from the Cα backbone compared to that of the wild-type CYP1A1 template. [b] DTIC orientation is based on the distance of the α-carbon targeted for *N*-dealkylation from the heme iron and its angle relative to the planar heme (see 'Methods and Materials').

Table 3. Holo-P450 yields for enzymes expressed in *E. coli*.

Enzyme	pmol P450/mg[a]
CYP1A1	141 ± 8
S116A	103 ± 7
S122A	56 ± 2
S122T	61 ± 0.5
F123A	9 ± 3
E161K	94 ± 9
E166Q	33 ± 7
V191M	225 ± 9
F224A	54 ± 12
V228T	95 ± 11
E256K	115 ± 36
Y259F	115 ± 5
N309T	132 ± 2
L312F	115 ± 4
D313A	57 ± 3
D313N	35 ± 3
G316V	165 ± 13
A317G	101 ± 5
D320A	223 ± 9
T321G	59 ± 2
T321P	59 ± 12
T321S	57 ± 2
V322A	27 ± 9
I386G	22 ± 7
I386V	42 ± 32
I458P	134 ± 26
I458V	89 ± 6
T497S	84 ± 5

[a]Expression levels shown as mean ± SD (n ≥ 3).

Table 4. Derived kinetic parameters for DTIC *N*-demethylase activity by wild-type CYP1A1 and mutant CYP1A1 enzymes

Enzyme	V_{max} (pmol/min/pmol P450)	K_m or S_{50} (µM)	V_{max}/K_m (µL/min/pmol P450)	Hill coefficient
CYP1A1[a]	**28 ± 4**	**408 ± 43**	**0.069**	**-**
S116A	26.7	412	0.065	-
S122A[b]	59.9	94332	-	0.50
S122T[b]	23.3	1132	-	0.70
F123A[b]	16.1	5237	-	0.80
E161K[a]	**30 ± 5**	**249 ± 22***	**0.120***	**-**
E166Q[b]	34.8	1492	-	0.80
V191M	23	501	0.046	-
F224A	31.4	468	0.067	-
V228T[a]	**32.4 ± 1.5**	**386 ± 22**	**0.090**	**-**
E256K[a]	**29 ± 3**	**238 ± 32***	**0.121***	**-**
Y259F	25.9	1082	0.024	-
N309T	33.9	533	0.064	-
L312F	32.7	773	0.042	-
D313A[b]	35.8	8749	-	0.80
D313N[b]	17.5	9990	-	0.80
G316V	19.7	6963	0.003	-
A317G[d]	21.1	12207	0.001	-
D320A	18.3	1091	0.017	-
T321G[b]	8.7	1117	-	0.70
T321P[b]	23.1	2543	-	0.75
T321S[b]	56.9	3119	-	0.60
V322A	32.2	680	0.047	-
I386G	nd[c]	nd	nd	nd
I386V[a]	**44.2 ± 4***	**765 ± 30***	**0.058**	**-**
I458P	33.1	587	0.056	-
I458V[a]	**22 ± 4**	**183 ± 61***	**0.118***	**-**
T497S[b]	33.5	1250	-	0.85

[a]K_m and V_{max} values are given as the mean ± SD of four experiments. [b]Data from fitting with the Hill equation. [c]No detectable activity. [d]The kinetic model for these mutants could not be characterized. *$p < 0.05$ compared to the corresponding parameter for the wild-type.

Figure 1

5-(3,3-dimethyltriazen-1-yl)-1-imidazole-4-carboxamide
(DTIC)

P450

5-(3-hydroxy-methyl-3-methyl-triazen-1-yl)-1-imidazole-4-carboxamide
(HMMTIC)

5-(3-methyl-triazen-2-yl)-1-imidazole-4-carboxamide

5-(3-methyl-triazen-1-yl)-1-imidazole-4-carboxamide
(MTIC)

$N_{2\,(g)}$ + CH_3^+ +

5-aminoimidazole-4-carboxamide
(AIC)

Figure 2

Figure 3

Figure 4

Figure 5

D253

E256K

F258

Y259

DTIC mutant

I-HELIX

DTIC wild-type

HEME